According to the December 25 news release issued by the Business Club, 144,600 bottles (calculated at 200IU/bottle) of prothrombin complexes were put on the market in China from January to October this year, an increase of nearly 30% from the same period of last year, and production capacity recovered significantly. The growth in the medical market segment demand (increased number of major diseases, artificial liver technology, organ transplants, etc.) has induced a slight increase in the market size. Although there are many alternatives available in clinical practice, the unique coagulation mechanism, efficacy, and safety of the product play an irreplaceable role in some special clinical fields. It is estimated that the product may have a total of 270,000 bottles issued in the year.
Only three of the local companies produce prothrombin complexes. In this market, Hualan Biological Technology Co., Ltd. topped the list with a 92% market share; Shanghai Lai Shi was ranked second, and its domestic product volume shrank significantly. However, the company’s production capacity depends on the amount of pulp extracted and the production batches. With the incompatibility of domestic listings, Shanghai's emerging products are less marketed, which is related to the very small amount of raw material plasma.
Coagulation Factor VIII: slow recovery of production capacity is difficult to meet
Factor VIII is an emergency medicine for the prevention and treatment of hemorrhage in hemophilia B patients. According to the batch release data of each drug inspection agency, from January to October this year, a total of 175,200 bottles of coagulation factor VIII (calculated at 200 IU/bottle) were issued and put on the market, which is an increase of about 44% compared with the same period of last year, but with many Chinese blood donors. Compared with the number of patients, it is difficult to meet the market's normal prevention needs and emergency drug requirements. The ideal supply volume should be 400,000 bottles. In this market, Anhui Green Cross won the top spot with a share of 58%; Hualan Bios ranked second; its increase in production capacity was related to the increase in pulping yield due to the adoption of the new law; Shanghai Lai Shi was ranked third and listed recently. 30,000 bottles.
Currently, patients with hemophilia need regular or regular medications to control the disease, but it is difficult to afford the related costs (the price of factor VIII is basically 2 yuan/IU, and the price of gene recombination factor is 5 yuan/IU). This is worth Social concerns.
Fibrinogen: High Threshold of Entry into the Enterprise
Fibrinogen is not a slow-moving product. Like other clotting factors, this product is important in some special clinical fields (such as heart surgery, obstetrics and gynecology and neonatal bleeding, major diseases, artificial liver technology, organ transplantation, etc.). Value. Even in emergency situations such as disaster incidents and battlefield rescue, the product also plays a large role. However, because of the high manufacturing process threshold, technical difficulties, and high prices, many companies are deterred from fibrinogen production.
From the issuance of data from January to October of this year, a total of 71,900 bottles (calculated at 0.5g/bottle) of fibrinogen were listed and circulated, representing an increase of 40% over the same period of last year. This was mainly due to the newly approved production of Hasschenken. In spite of this, the volume of the product is still falling a lot during the peak period. In the fibrinogen market, Shanghai Lai Shi, Hussein, and Shanghai Xinxing are among the top three. Hua Lan Bio, Boya, and Zhongsheng Group's Shanghai-based companies that have approval numbers have not seen batch approval records. (See Figure 8 for details)
Fibrinogen is neglected in the blood product chain. As mentioned earlier, many areas of medicine are inseparable from fibrinogen. Although there are alternatives such as frozen plasma FFP and cryoprecipitate, the clinical importance of fibrinogen should not be underestimated. Once outbreaks of dangerous accidents, natural disasters, wars, etc., fibrinogen is a key strategic drug substance, and its demand is huge at a particular time.
Intramuscular injection of gamma globulin: high cost performance and great market potential
From January to October of this year, all drug testing institutes issued batches of 644,700 bottles of intravenous gamma globulin products (calculated at 150 mg/bottle), a decrease of 62% from the same period last year. In general, it is not economically feasible for companies to use inexpensive plasma components to produce inexpensive intramuscular gamma globulin. In 2009, many companies put more stock plasma components into production and caused an increase in the volume of the product. This year, many companies switched their plasma components to other more profitable products (such as static propylene and special immunoglobulins), resulting in a drop in the production of intramuscular gamma globulin.
Intramuscular injection of gamma globulin is a well-selling evergreen variety in the market due to its ease of use and its great advantage over intravenous gamma globulin (price ratio of 1:12). In addition, due to the spread of special outbreaks (such as "hand-foot-mouth disease") in recent years, clinical and preventive organizations have chosen to prefer the cost-effective intramuscular injection of gamma globulin, which has also expanded the latter's market demand.
Lots issued data show that in the intramuscular injection of gamma globulin market, Shandong Taibang takes the first place with 30%; Zhongshang Group Shanghai Institute and Hualan Biological Subsequent; previous years, the large family of Zhongsheng Group Lanzhou did not see production and Lots of records have been issued, and many companies with document numbers have also stopped producing the product. However, from the perspective of the first line of prevention and clinical application, the safety and convenience advantages of high-cost intramuscular injection of gamma globulin are affected by the increase in the price of intravenous gamma globulin, and it is expected that the product market has great potential for development.
Only three of the local companies produce prothrombin complexes. In this market, Hualan Biological Technology Co., Ltd. topped the list with a 92% market share; Shanghai Lai Shi was ranked second, and its domestic product volume shrank significantly. However, the company’s production capacity depends on the amount of pulp extracted and the production batches. With the incompatibility of domestic listings, Shanghai's emerging products are less marketed, which is related to the very small amount of raw material plasma.
Coagulation Factor VIII: slow recovery of production capacity is difficult to meet
Factor VIII is an emergency medicine for the prevention and treatment of hemorrhage in hemophilia B patients. According to the batch release data of each drug inspection agency, from January to October this year, a total of 175,200 bottles of coagulation factor VIII (calculated at 200 IU/bottle) were issued and put on the market, which is an increase of about 44% compared with the same period of last year, but with many Chinese blood donors. Compared with the number of patients, it is difficult to meet the market's normal prevention needs and emergency drug requirements. The ideal supply volume should be 400,000 bottles. In this market, Anhui Green Cross won the top spot with a share of 58%; Hualan Bios ranked second; its increase in production capacity was related to the increase in pulping yield due to the adoption of the new law; Shanghai Lai Shi was ranked third and listed recently. 30,000 bottles.
Currently, patients with hemophilia need regular or regular medications to control the disease, but it is difficult to afford the related costs (the price of factor VIII is basically 2 yuan/IU, and the price of gene recombination factor is 5 yuan/IU). This is worth Social concerns.
Fibrinogen: High Threshold of Entry into the Enterprise
Fibrinogen is not a slow-moving product. Like other clotting factors, this product is important in some special clinical fields (such as heart surgery, obstetrics and gynecology and neonatal bleeding, major diseases, artificial liver technology, organ transplantation, etc.). Value. Even in emergency situations such as disaster incidents and battlefield rescue, the product also plays a large role. However, because of the high manufacturing process threshold, technical difficulties, and high prices, many companies are deterred from fibrinogen production.
From the issuance of data from January to October of this year, a total of 71,900 bottles (calculated at 0.5g/bottle) of fibrinogen were listed and circulated, representing an increase of 40% over the same period of last year. This was mainly due to the newly approved production of Hasschenken. In spite of this, the volume of the product is still falling a lot during the peak period. In the fibrinogen market, Shanghai Lai Shi, Hussein, and Shanghai Xinxing are among the top three. Hua Lan Bio, Boya, and Zhongsheng Group's Shanghai-based companies that have approval numbers have not seen batch approval records. (See Figure 8 for details)
Fibrinogen is neglected in the blood product chain. As mentioned earlier, many areas of medicine are inseparable from fibrinogen. Although there are alternatives such as frozen plasma FFP and cryoprecipitate, the clinical importance of fibrinogen should not be underestimated. Once outbreaks of dangerous accidents, natural disasters, wars, etc., fibrinogen is a key strategic drug substance, and its demand is huge at a particular time.
Intramuscular injection of gamma globulin: high cost performance and great market potential
From January to October of this year, all drug testing institutes issued batches of 644,700 bottles of intravenous gamma globulin products (calculated at 150 mg/bottle), a decrease of 62% from the same period last year. In general, it is not economically feasible for companies to use inexpensive plasma components to produce inexpensive intramuscular gamma globulin. In 2009, many companies put more stock plasma components into production and caused an increase in the volume of the product. This year, many companies switched their plasma components to other more profitable products (such as static propylene and special immunoglobulins), resulting in a drop in the production of intramuscular gamma globulin.
Intramuscular injection of gamma globulin is a well-selling evergreen variety in the market due to its ease of use and its great advantage over intravenous gamma globulin (price ratio of 1:12). In addition, due to the spread of special outbreaks (such as "hand-foot-mouth disease") in recent years, clinical and preventive organizations have chosen to prefer the cost-effective intramuscular injection of gamma globulin, which has also expanded the latter's market demand.
Lots issued data show that in the intramuscular injection of gamma globulin market, Shandong Taibang takes the first place with 30%; Zhongshang Group Shanghai Institute and Hualan Biological Subsequent; previous years, the large family of Zhongsheng Group Lanzhou did not see production and Lots of records have been issued, and many companies with document numbers have also stopped producing the product. However, from the perspective of the first line of prevention and clinical application, the safety and convenience advantages of high-cost intramuscular injection of gamma globulin are affected by the increase in the price of intravenous gamma globulin, and it is expected that the product market has great potential for development.
1.Powdered or Powdered free .
2.Yellow colour ,hospital medical examination or cleaning glove and others.
3. CE,FDA510K ,EN455,EN374,ISO9001,ISO13485 Certifications etc.
4.AQL:1.5,2.50,4.0 ;Medical grade and Industrial grade ,food grade ,electronic grade etc.
5.Size: S,M,L,XL,XL etc. and weight as your requirement.
6.no latex and non sterile
7.beaded cuff;sigle use only
8.soft and comfortable.
9.OEM or ODM packing.
10.usage widely for hospital medical examination,health care,hotel ,restaurant ,home cleaning etc
Yellow Vinyl Glove
Yellow Vinyl Glove,Hotel Glove,Yellow Disposable Vinyl Gloves,Yellow Color Vinyl Gloves
Zibo Hongye Shangqin Medical Science and Technology Co.,Ltd. , https://www.vinylgloves.cn